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Abstract
Biallelic mutations in IGHMBP2 cause spinal muscular atrophy with respiratory distress type 1 (SMARD1) or Charcot–Marie–Tooth type 2S
(CMT2S). We report three families variably affected by IGHMBP2 mutations. Patient 1, an 8-year-old boy with two homozygous variants: c.2T>C
and c.861C>G, was wheelchair bound due to sensorimotor axonal neuropathy and chronic respiratory failure. Patient 2 and his younger sister,
Patient 3, had compound heterozygous variants: c.983_987delAAGAA and c.1478C>T. However, clinical phenotypes differed markedly as the
elder with sensorimotor axonal neuropathy had still unaffected respiratory function at 4.5 years, whereas the younger presented as infantile spinal
muscular atrophy and died from relentless respiratory failure at 11 months. Patient 4, a 6-year-old girl homozygous for IGHMBP2 c.449+1G>T
documented to result in two aberrant transcripts, was wheelchair dependent due to axonal polyneuropathy. The clinical presentation in Patients 1
and 3 were consistent with SMARD1, whereas Patients 2 and 4 were in agreement with CMT2S.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Immunoglobulin mu-binding protein 2 (IGHMBP2) is a
ubiquitously expressed DNA and RNA helicase [1–3]. Biallelic
mutations in this gene result in degeneration of α-motor neurons
in the brain stem and the anterior horns of the spinal cord,
causing spinal muscular atrophy with respiratory distress type
1 (SMARD1; OMIM 604320) or Charcot–Marie–Tooth type
2S (CMT2S; OMIM 616155). IGHMBP2 is implicated in
transcription [4,5], pre-mRNA processing [2,6], translation [5,7,8],
and immunoglobulin class switching [2]. Mutated IGHMBP2
is suggested to result in a deficiency of maturation of mRNAs
in neurons, thereby leading to neuronal degeneration [1].
SMARD1 is characterized by infantile onset severe axonal
polyneuropathy and diaphragmatic paralysis [4,9–11]. Typically
SMARD1 patients die within the first year of life due to
respiratory failure [4,10,11]. However, the disease severity in
SMARD1 may be variable, and juvenile onset of respiratory
distress [12–15] with survival up to 20 years has been reported
[14,16]. At the mild end of the IGHMBP2 mutation disease
spectrum, patients present with CMT2S, a sensorimotor axonal
polyneuropathy, usually with less pronounced neurophysiological
changes compared to SMARD1, relatively spared respiratory
function, and longer survival [1,15,17].
Here we describe four individuals from three families with
biallelic mutations in IGHMBP2. The common denominator for
referral of these patients was gross motor delay. We identified
four mutations in IGHMBP2. The clinical presentation
in the patients varied from SMARD1 to CMT2S, even
within one family. We also show for the first time that the
IGHMBP2 c.449+1G>T variant results in two aberrant
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transcripts, both containing a premature termination codon
(PTC).
2. Case report
2.1. Clinical description
2.1.1. Family A
Patient 1, a boy, was the second child of healthy first-degree
cousins of Pakistani origin (Fig. 1a). When assessed at a routine
health check-up at 6 months, he was noted to be hypotonic with
protrusion of the right side of his thorax. Motor development
was significantly delayed and at 2.5 years he could only walk a
few steps using an orthosis. He had distal muscular atrophy of
the upper and lower extremities, hypermobile joints and absent
reflexes. At 5 years he had profound distal weakness and poor
head control. He was no longer able to sit or walk, and had
become wheelchair dependent. He had dysphagia and a weak
cough and suffered from chronic respiratory distress that
required ventilatory support during sleep. From 5.5 years he
was completely dependent on ventilatory support and also
required a cough assist machine. At 6 years his extremities were
paralyzed, except for preservation of some movement with his
fingers. Feeding was difficult, necessitating a gastric feeding
tube.
Neurophysiological examinations at 2 years showed lack of
responses from both motor nerves (median, tibial and peroneal
in his right extremities) and from the median sensory nerve. At
the age of 5 years he still lacked both motor responses from the
median, ulnar, tibial and peroneal nerves and sensory responses
from the median, ulnar, sural and superficial peroneal nerves.
However, there were responses from the sensory radial nerves
(amplitude 3.0–5.2 μV and nerve conduction velocities (NCVs)
35–36 m/s). Needle-electromyography (EMG) of the anterior
tibial and lateral vastus muscles at age 2 years and the lateral
vastus and deltoid muscles at age 5 years showed spontaneous
activity with fibrillation potentials in at least one muscle each
time and at age 2 also some neurogenic motor unit potentials.
However, due to muscle atrophy it was generally difficult to
judge activity in the muscles. A biopsy of the sural nerve at 6
years showed lack of myelinated fibers. The results of these
examinations were compatible with a pronounced sensorimotor
axonal neuropathy. Ultrasound examination of his chest
revealed reduced diaphragm motility. Echocardiography and
cognitive function were normal.
2.1.2. Family B
Patients 2 and 3 were siblings, born to non-consanguineous
healthy parents of Norwegian origin (Fig. 1b).
Patient 2, a boy, appeared normal at birth, but soon
developed contractures of the Achilles tendons, progressing
to pes cavus with forefoot adduction between 4 and 8 months.
Although he learned to walk before 15 months, peripheral
neurogenic problems persisted, making him dependent on
orthosis for walking at 20 months. At this stage, atrophy of the
calf muscles and weakness for dorsiflexion of the ankles were
noted. The upper extremities had also become mildly affected
with contractures of the fingers. The deep tendon reflexes were
Fig. 1. a) Pedigree of family A showing the segregation of two variants in IGHMBP2 c.2T>C and c.861C>G. Both IGHMBP2 variants were found in cis in
heterozygosity in the parents and in homozygosity in Patient 1. b) Pedigree of family B showing the segregation of the IGHMBP2 c.1478C>T and
c.983-987delAAGAA variants (indicated in black), parents were carriers. Patient 3 also had a de novo c.14092_14093insTA in MLL2 (indicated in grey). c) Pedigree
of family C showing the segregation of the IGHMBP2 c.449+1G>T variant. d) Image from Alamut Visual Software (Rouen, France) showing the evolutionary
conservation of the amino acid changes resulting from the two variants c.2T>C (p.1M?) and c.861C>G (p.Ser287Arg) in Patient 1 Family A (black stars).
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absent. Pectus excavatum was noted at 4.5 years, but he had not
shown signs of respiratory dysfunction.
Neurophysiological examination performed at 18 months
showed pathologically low motor amplitudes from all nerves
tested (right median 2.2mV, right ulnar 0.3 mV and the tibial
nerves bilaterally 0.2-07 mV, no response from peroneal
nerves). It was only possible to measure the NCV in the median
nerve and this was slightly delayed (34.6 m/s; reference values
for NCV used in this study are based on Miller and Kuntz [18]).
Sensory nerve conduction velocities ranged between 38.5 m/s
in the ulnar nerve (normal range between 13 and 24 months is
41.3–63.5 m/s) and 56.3 m/s in the median nerve, 38.7 m/s in
the sural nerve and 57.3 m/s in the peroneal superficial nerve.
The sensory amplitudes were also pathologically low, ranging
from 3.6 to 3.9 μV in the median and ulnar nerves, respectively,
and 2.9–3.6 μV in the sural and peroneal superficial nerves.
EMG of the anterior tibial and lateral vastus muscles showed
spontaneous activity. These findings suggested sensorimotor
axonal polyneuropathy with motor nerve fibers more affected
than sensory nerve fibers. This was confirmed by similar
findings in a repeated neurophysiological examination less than
3 months later when EMG also showed chronic neurogenic
findings in the anterior tibial muscles bilaterally. Ultrasound
examination of the diaphragm at 3 years showed normal
motility, and overnight monitoring of pO2 and pCO2 was also
normal. His cognitive development was normal.
Patient 3, a girl, was born at 36 weeks of gestation after an
uncomplicated pregnancy, with birth weight and length at the
3rd centiles, and head circumference 1 cm below the 3rd centile.
She was admitted to the neonatal intensive care unit with
feeding difficulties and hypotonia. She exhibited dysmorphic
features that included widely spaced eyes, elongated palpebral
fissures, long eyelashes, high-arched and interrupted eyebrows,
fetal pads, and pectus excavatum, suspected to be due to Kabuki
syndrome (OMIM 147920). She was hospitalized at 1 month
due to feeding difficulties and at 5 months due to urosepsis.
Motor development was severely delayed and at 8 months she
could not crawl, whereas the deep tendon reflexes were difficult
to elicit. When hospitalized due to a pulmonary infection at
age 8 months, she showed paradoxical movements of the
diaphragm, indicating muscle weakness. Upon the acute
respiratory distress caused by the pulmonary infection, she
developed a chronic respiratory failure with increasing need
for ventilator support. Neurophysiological examinations were
suggestive of motor axonal polyneuropathy with low motor
amplitudes both for the median (1.1 mV) and ulnar nerve (2.2 mV)
in the right upper extremity and for the tibial nerves bilaterally
in the lower extremities (0.4–2.2 mV). The NCVs were within
normal range (38.5–59 m/s). No motor responses were detected
from the peroneal nerves bilaterally. Only two sensory nerves
were examined, the right median and left peroneal superficial
nerves, and they were within normal range for her age (amplitudes
15 and 4.7 respectively and NCV 48 and 40 m/s). EMG-recordings
in the anterior tibial muscles bilaterally and from the left vastus
and right deltoid muscles revealed no spontaneous activity.
She died at 11 months due to chronic respiratory failure. Cerebral
MRI was normal.
2.1.3. Family C
Patient 4, a girl, was the first child of healthy parents of
Kurdish origin, reported to be unrelated (Fig. 1c).
She was referred from the public health station for children
at 13 months due to delayed motor development, as she was
hypotonic and could sit only with support. She walked with
support at 22 months. On examination at 2 years, distal muscle
atrophy, foot deformities with valgus positioning of the right
foot, varus positioning of the left foot and hyperextension of
the knees were observed. At 6 years, the deep tendon reflexes
were noted to be absent and she required orthosis in order to
stand and walk. She was easily fatigued and mostly wheelchair
dependent. At the same age she was evaluated by cough peak
expiratory flow (PEF), spirometry and nocturnal transcutaneous
registration of carbon dioxide and oxygen saturation, showing
a weak cough, but no signs of hypoventilation (movements of
the diaphragm were not evaluated). She started to use a cough
assist machine. Slow recovery from respiratory tract infections
became evident. She underwent surgery for bilateral clubfeet.
The ability to swallow liquids and solids was impaired to such
an extent that she needed the insertion of a percutaneous gastric
tube. Neurophysiological examination at 28 months showed
low motor amplitudes in the right median (2.5 mV) and bilaterally
in the tibial nerves (0.6 and 2.0 mV respectively) and with
only a very small response (0.1 mV) in one of the two peroneal
nerves tested. The conduction velocities were delayed, 38.7 m/s
in the median nerve and from 25.1 to 28.7 m/s in the lower
extremities. There was no sensory response from the sural
nerve, but a slightly lowered response from the median nerve
(5.9 μV) with a conduction velocity of 40 m/s. EMG from
both anterior tibial muscles showed spontaneous activity and
during voluntary activity there were a few neurogenic motor
unit potentials. The findings were compatible with sensorimotor
axonal polyneuropathy. Echocardiography and cognitive
development were normal.
2.2. Molecular analyses
2.2.1. Family A
Whole exome sequencing (WES) was performed in
Patient 1 and his parents. Data analysis assuming autosomal
recessive mode of inheritance identified two homozygous
variants in IGHMBP2 (NM_002180.2): c.2T>C; p.Met1?
(chr11:hg19.g:68,671,422 bp) and c.861C>G; p.Ser287Arg
(chr11:hg19.g:68,682,440 bp) in the patient, while both parents
were found to be heterozygous for both variants (Fig. 1a)
(Complete list of gene variants is provided in Table S1). Additional
experimental WES details are in Supplementary File S1. Sanger
sequencing verified the variants (all primer sequences used in
this study are given in Table S2). The c.2T>C variant was
previously identified in two patients clinically presenting with
CMT1 by targeted gene panel sequencing [19]. IGHMBP2
c.2T>C alters the start codon and is predicted to abolish protein
production. The variant was not reported in the ExAC database
(http://exac.broadinstitute.org), including more than 60,000
exomes. The closest alternative in-frame initiation codon was
found at p.338, which is likely to be too distant to be utilized
[20], and if used it would result in protein truncation in the
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crucial helicase domain [4,5,8]. Also, no alternative Kozak
consensus sequence, 5′GCCGCCRMCATGGCG′3 (R = A or
G and M = A or C), suggestive of an alternative start of translation
[19,20], was found. In addition, another IGHMBP2 variant,
c.861C>G, was homozygous in Patient 1 and heterozygous in
the parents. This missense variant in exon 6 changes a highly
conserved amino acid in the helicase domain (Fig. 1d). ExAC
database reported that IGHMBP2 c.861C>G was found in
heterozygosity in 55 out of 8255 individuals from South Asia
(allele frequency 0.0033). Neither of the c.2T>C and c.861C>G
variants were identified by Sanger sequencing in 166 healthy
Pakistani individuals. In order to investigate if the c.2T>C
variant would affect the transcript level, the IGHMBP2 mRNA
level was measured in Patient 1, his parents and six controls.
The analysis showed similar levels in all individuals tested
(Fig. 2).
2.2.2. Family B
Sanger sequencing of IGHMBP2 was performed in Patient
3 based on the clinical presentation. A frameshift deletion in
IGHMBP2 exon 7, c.983_987delAAGAA; p.Lys328Thrfs46*
(chr11:hg19.g:68,685,274-68,685,278), and a missense in
IGHMBP2 exon 10, c.1478C>T; p.Thr493Ile (chr11:
hg19.g:68,701,322) were identified. Sanger sequencing showed
that Patient 2 also had both variants, and that the
c.983_987delAAGAA and c.1478C>T were of maternal and
paternal origins, respectively (Fig. 1b). Both variants were
previously reported in SMARD1 patients [5,10,12,21]. Patient
3 also had Kabuki syndrome (OMIM 147920), due to a de
novo c.14092_14093insTA mutation in myeloid/lymphoid or
mixed-lineage leukemia protein 2 (MLL2) (identified by Sanger
sequencing). In order to investigate if the IGHMBP2
c.983_987delAAGAA or c.1478C>T variants result in nonsense-
mediated mRNA decay (NMD), the IGHMBP2 mRNA levels
were measured by qRT-PCR in Patient 2, his parents and six
controls, showing a higher level in the patient and similar
levels in parents and controls (Fig. 2).
2.2.3. Family C
In Patient 4 a homozygous IGHMBP2 c.449+1G>T
(chr11:hg19.g:68,675,806) splice donor site variant in intron 3
was identified by WES after analyzing a set of candidate genes
(Table S3) based on clinical presentation. Sanger sequencing
confirmed that Patient 4 was homozygous and the parents were
heterozygous for the variant (Fig. 1c). The c.449+1G>T variant
was previously reported in patients with SMARD1 and CMT2S
[15,22]. Exons 3–5 in the IGHMBP2 transcript were amplified
by reverse-transcriptase PCR (RT-PCR) in Patient 4, her parents
and six controls in order to identify possible aberrant transcripts
resulting from the c.449+1G>T variant. The gel image showed
a band representing the normal transcript in the controls (Fig. 3,
band 1), which was absent in Patient 4. Instead the patient had
two bands representing abnormal transcripts that were not present
in the controls (Fig. 3, bands 2 and 3). All three bands were
found also in the heterozygous parents (Fig. 3). Sanger sequencing
Fig. 2. Relative IGHMBP2 mRNA levels measured by qRT-PCR in patients
and parents in families A and B compared to the mean level in six controls,
showing similar levels to controls in family A, and similar to increased levels in
family B. Family A: Patient 1 with the two homozygous variants c.2T>C and
c.861C>G and his parents heterozygous for both variants. Family B: Patient 2
with compound heterozygous variants c.1478C>T and c.983-987delAAGAA,
and his heterozygous parents for the c.1478C>T and c.983-987delAAGAA
variants, respectively. The mean level in the six controls is shown with 95%
confidence interval.
Fig. 3. a) Gel image of the RT-PCR products for exons 3–5 of the IGHMBP2 transcript from the patient and parents from family C and six controls, showing that
the band representing the normal transcript is absent in the patient with the homozygous splice variant c.449+1G>T (band 1), and instead the presence of bands 2
and 3 not seen in the controls. All three bands were detected in the parents with the heterozygous c.449+1G>T variant. This shows that the splice site variant
c.449+1G>T results in two aberrant transcripts, and by Sanger sequencing of cDNA from bands 2 and 3, these were shown to have a full 196 bp intron 3 retention
and a partial 100 bp intron 3 retention, respectively. b) Drawing of the content of bands 1, 2, and 3 based on Sanger sequencing results.
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of band 2 in the patient showed a 100 bp intron 3 partial
retention (chr11:hg19.g:68,675,806-68,675,906 bp), and Sanger
sequencing of band 3 showed full 196 bp intron 3 retention
(chr11:hg19.g:68,675,806-68,676,001 bp). Both aberrant
transcripts have a PTC at c.449+2-c.449+4 (p.Lys150Asnfs*0),
and are expected to result in NMD or a truncated protein.
The likely disease causing IGHMBP2 variants reported
in the study are present in the Clinical Variant
database (http://www.ncbi.nlm.nih.gov/clinvar/) with the
following accession numbers: c.2T>C: SCV000255975;
c.983_987delAAGAA: SCV000255976; c.1478C>T:
SCV000255977; c.983_987delAAGAA: SCV000255978;
c.1478C>T: SCV000255979; c.449+1G>T: SCV000255980.
3. Discussion
We identified four likely disease causing mutations in
IGHMBP2 in four patients from three independent families
(c.2T>C, c.449+1G>T, c.1478C>T and c.983_987delAAGAA).
Patient 1 (consanguineous family; Fig. 1a) had neurophysiological
findings indicating a severe sensorimotor axonal neuropathy
with onset of respiratory distress at 5 years, consistent with
SMARD1. His neurophysiological findings could also be
compatible with spinal muscular atrophy with an additional
component of sensory neuropathy as previously described in
SMARD1 [4,10]. At 8 years, he was wheelchair bound and in
need of continuous respiratory support. He was found by WES
to have a homozygous c.2T>C mutation in IGHMBP2, previously
reported in two patients clinically presenting with CMT1 [19].
The lack of alterative in-frame initiation codons in the vicinity
of the original initiation codon indicates that the c.2T>C variant
likely abolishes protein translation, thus it was considered to
be the cause of the disease in this patient. In addition, he had a
second homozygous variant c.861C>G, which has been reported
with an allele frequency of 0.0033 in the South Asian population
in the ExAC database. Since SMARD1 is recognized as an
extremely rare disorder [16], the relatively high allele frequency
of the c.861C>G variant indicates it is a non-pathogenic rare
genetic variant. In any case, the c.861C>G is not expected to
have an impact on IGHMBP2 in Patient 1, because the c.2T>C
variant likely abolishes protein production.
The siblings, Patients 2 and 3 (Fig. 1b), were compound
heterozygous for two IGHMBP2 mutations: c.1478C>T and
c.983_987delAAGAA. There was considerable clinical variability
as Patient 3 had SMARD1 and died at 11 months due to
respiratory failure, whereas her brother, Patient 2, had a more
typical axonal CMT2S phenotype without signs of respiratory
distress at 4.5 years. In two families with IGHMBP2 mutations
a large degree of intrafamilial variability was described [15,23].
Intrafamilial variability may result from modifier variants in
other genes or from variation in the residual level of IGHMBP1.
Having Kabuki syndrome may have predisposed patient 3 to
the pulmonary infection [24], which caused acute respiratory
distress at age 8 months, after which the patient developed
chronic respiratory distress.
The c.1478C>T was previously described in five patients
from four families with compound heterozygous mutations
[5,12,23,25]. The onset of respiratory distress ranged from 6
months to 10 years in four of these patients [5,23,25], and the
fifth patient had normal respiratory function at 12 years [12].
A single patient with the c.983_987delAAGAA mutation in a
homozygous state had SMARD1 and infantile onset of respiratory
distress [10]. In our study, expression of the IGHMBP2 mRNA
indicated that the c.2T>C, c.983_987delAAGAA and c.1478C>T
variants did not result in NMD (Fig. 2). This is in accordance
with previous analysis showing that IGHMBP2 mutations do
not lead to reduced mRNA levels [12,26]. In the absence of
NMD, the c.983_987delAAGAA is predicted to result in protein
truncation, the c.2T>C is predicted to abolish protein translation
and the c.1478C>T is predicted to directly affect the protein
function.
Patient 4 (Fig. 1c), had predominantly axonal motor
polyneuropathy and was mostly wheelchair dependent. At 6
years of age, only a weak cough indicated she might have mild
respiratory muscle dysfunction. She was homozygous for
IGHMBP2 c.449+1G>T, previously reported in three patients:
one with typical SMARD1 and onset of respiratory distress at 4
months [22] and two siblings with axonal sensory motor
neuropathy, one with late-onset respiratory distress at 15 years,
and one still without respiratory problems at 22 years [15].
IGHMBP2 c.449+1G>T is a rare variant, since it is not reported
in the ExAC database (search October 21, 2015), but it was
found in two consanguineous families, one from Lebanon [15]
and one from Kurdistan [22] (similar ethnicity as family C).
This variant may therefore have a founder in the Middle East. In
this report we show that IGHMBP2 c.449+1G>T variant results
in a full intron 3 retention, in addition to a previously described
partial intron 3 retention [15] (Fig. 3), both predicted to result in
NMD or a truncated protein with lack of function.
Two of our patients presented with SMARD1 (Patients 1 and
3), whereas the clinical phenotypes in the other two patients
were in agreement with CMT2S (Patients 2 and 4), but late
onset of respiratory distress cannot be excluded. However,
prognostication based on the genotype is difficult, as
neurophysiological findings overlap [1,15,22], and respiratory
distress may present at a substantially later age, or even not
occur at all [14,15].
4. Conclusion
Our study confirms that biallelic IGHMBP2 mutations either
may cause SMARD1 or CMT2S. In fact, phenotypic diversity
may occur within the same family, as identical compound
heterozygous mutations in siblings segregated as SMARD1 and
CMT2S, exhibiting the severe and moderate phenotypes
of the disease spectrum. We did not detect NMD of IGHMBP2
mRNA resulting from the c.2T>C, c.983_987delAAGAA or
c.1478C>T variants, indicating these variants affect the protein
level or function directly. The IGHMBP2 c.449+1G>T variant
was shown to result in two aberrant transcripts, which may be
degraded by NMD or alternatively produce a truncated protein.
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